NICE approves denosumab for postmenopausal fracture prevention

Postmenopausal women at risk of fractures can now be treated with denosumab (Prolia) on the NHS.

Given as a subcutaneous injection twice a year, denosumab inhibits the RANK ligand – a key regulator of bone-resorbing osteoclasts.
Given as a subcutaneous injection twice a year, denosumab inhibits the RANK ligand – a key regulator of bone-resorbing osteoclasts.

NICE has recommended denosumab as an option for the primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women for whom the recommended bisphosphonates are unsuitable.

Specifically, eligible patients must:

  • be unable to comply with the administration instructions for alendronate and either risedronate or etidronate, or
  • have an intolerance of, or a contraindication to, these treatments.

In addition, the guidance states that the antibody should be used for primary prevention only when the woman’s T-score is at or below the following values:

No. of independent clinical risk factors for fracture*
Age  (years) 0 1 2
65-69 Not recommended -4.5 -4.0
70-74 -4.5 -4.0 -3.5
75 or older -4.0 -4.0 -3.0

*Parental history of hip fracture, alcohol intake of 4 or more units per day, rheumatoid arthritis.

People already receiving denosumab for the prevention of osteoporotic fractures who do not meet the above criteria should be able to continue treatment until they and their doctor decide it is appropriate to stop, says NICE.

NICE guidance on denosumab

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Third tiotropium inhaler adds to treatment options for COPD patients

Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...